CAI
Caris Life Sciences, Inc. Health Care Services-Medical Laboratories Russell 3000
$34.33Close
$9.7BMarket cap
$14.55 – $36.1452-week range
Nov 4, 2026Next report · after the close
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 97 · stronger than 97% of stocks over 12 months
- Volume drying up last 10 days 36% under the 50-day average
Cautions
- Results soon Nov 4, 2026, in 3 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
5%
1wk
up 7.3%
price change
1mo
up 12.1%
price change
12-month return
up 10%
market up 11% ·
its own up 6%
F-score
—
— Not assessed
Altman Z″
-0.93
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
16.8×
price / book
Earnings yield
up 0.5%
EBIT / enterprise value
Cheaper than
20%
of the market · expensive
Revenue growth
up 97%
year on year
EPS growth
—
latest quarter
Sales growth
up 45%
latest quarter · -33 pts
ROE
down 12%
return on equity
Free cash margin
up 8%
$66.9M FCF
D/E
0.66
long-term debt / equity
Net debt / EBITDA
-6.2×
net cash
Interest cover
0.8×EBIT / interest
Piotroski tests
Repair signals
- FCF turned positive ($-254M → $67M)
Trade setup
ATR%
5.5%
$1.89 a day · 2×ATR $30.56
RS
97 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
0.8×
vs 50-day average
Up/down volume
1.03
50 sessions
Implied move
—
no option chain · report Nov 4, 2026
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Interest is covered, but thinly Earnings before interest cover the interest bill 0.8 times, leaving little room if profits fall.
- Shareholders diluted The share count rose 674.0% over the year, from 37m to 283m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 5, 2026
Results reaction
Aug 5, 2026+25% vs market2 sessions after results
Financials
- Net -8%
- Free cash 8%
- Cash
- Long-term debt
| FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|
| Revenue | $306.1M | $412.3M | $812.0M |
| Operating income | -$319.6M | -$257.1M | $45.1M |
| Net income | -$341.4M | -$281.9M | -$68.1M |
| Net margin | -112% | -68% | -8% |
| Earnings per share | -$9.77 | -$7.94 | -$0.41 |
| Free cash flow | -$298.4M | -$253.6M | $66.9M |
| Free cash margin | -97% | -62% | 8% |
| Cash | — | $64.0M | $796.3M |
| Long-term debt | — | $319.4M | $378.8M |
| Shareholders' equity | -$2.1B | -$2.5B | $577.3M |
| Shares outstanding | — | 36.50m | 282.53m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 5, 2026 | Quarterly ↗ | Jun 30, 2026 | 36d |
| May 8, 2026 | Quarterly ↗ | Mar 31, 2026 | 38d |
| Mar 3, 2026 | Annual ↗ | Dec 31, 2025 | 62d |
| Nov 5, 2025 | Quarterly ↗ | Sep 30, 2025 | 36d |
| Aug 12, 2025 | Quarterly ↗ | Jun 30, 2025 | 43d |
Current reports
| Filed | Disclosed |
|---|---|
| Sep 14, 2026 | Regulation FD ↗ |
| Aug 5, 2026 | Results ↗ |
| Jun 5, 2026 | Shareholder vote ↗ |
| May 7, 2026 | Results ↗ |
| Apr 2, 2026 | Material agreement · Agreement ended · New obligation ↗ |
| Feb 26, 2026 | Results · Regulation FD ↗ |
| Jan 12, 2026 | Results · Regulation FD ↗ |
| Nov 5, 2025 | Results ↗ |
| Oct 30, 2025 | Holder rights changed · Charter or bylaws ↗ |
| Aug 12, 2025 | Results ↗ |
| Jun 20, 2025 | Charter or bylaws · Other events ↗ |